* Guardant360® CDx is the first blood-based companion diagnostic to be approved inJapan for the d...
PALO ALTO, Calif., Jan. 8, 2024 /PRNewswire/ -- Guardant Health, Inc. (Nasdaq: GH), a leading preci...
SINGAPORE, Nov. 13, 2023 /PRNewswire/ -- Guardant Health, Inc. (Nasdaq: GH), a leading precision on...
* Guardant360® CDx is a comprehensive genomic profiling blood test that provides critical informa...
Collaboration will provide biopharmaceutical companies access to Guardant Health's broad portfolio ...
TOKYO, March 14, 2022 /PRNewswire/ -- The Ministry of Health, Labour and Welfare (MHLW) has granted...
TOKYO, Feb. 3, 2021 /PRNewswire/ -- Guardant Health Japan, an affiliate of Guardant Health Asia,Mid...
SINGAPORE, Aug. 8, 2020 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved G...
SINGAPORE, May 30, 2020 /PRNewswire/ -- According to the data presented at the American Society of ...
SINGAPORE, Nov. 22, 2019 /PRNewswire/ -- Guardant Health AMEA has won Frost & Sullivan's Growth E...